AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
290.23B
Market cap290.23B
Price-Earnings ratio
28.42
Price-Earnings ratio28.42
Dividend yield
1.68%
Dividend yield1.68%
Average volume
1.81M
Average volume1.81M
High today
$187.98
High today$187.98
Low today
$184.44
Low today$184.44
Open price
$186.91
Open price$186.91
Volume
2.25M
Volume2.25M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$132.32
52 Week low$132.32

Stock Snapshot

AstraZeneca(AZN) stock is priced at $187.15, giving the company a market capitalization of 290.23B. It carries a P/E multiple of 28.42 and pays a dividend yield of 1.7%.

On 2026-04-28, AstraZeneca(AZN) stock traded between a low of $184.44 and a high of $187.98. Shares are currently priced at $187.15, which is +1.5% above the low and -0.4% below the high.

AstraZeneca(AZN) shares are trading with a volume of 2.25M, against a daily average of 1.81M.

During the past year, AstraZeneca(AZN) stock moved between $132.32 at its lowest and $212.71 at its peak.

During the past year, AstraZeneca(AZN) stock moved between $132.32 at its lowest and $212.71 at its peak.

AZN News

TipRanks 36m
FDA Recruits AstraZeneca, Amgen in Bet on AI to Accelerate Drug Development

The U.S. Food and Drug Administration (FDA) is looking to deploy artificial intelligence to achieve real-time evaluation of clinical trial results to accelerate...

TipRanks 1h
Overhang should lift for Guardant after AstraZeneca AdCom, says Leerink

Leerink notes that Guardant Health (GH) shares have reacted negatively to the release of FDA briefing documents for AstraZeneca’s (AZN) camizestrant Advisory Co...

TipRanks 14h
AstraZeneca Wins First U.S. Asthma Approval for Triple-Inhaler Breztri

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More AZN News

The Wall Street Journal 1d
Health Care Roundup: Market Talk

yves herman / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk
TipRanks 5d
AstraZeneca Advances New Imaging Tool in Targeted Lung Cancer Trial

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper de...

TipRanks 6d
AstraZeneca Board Member Rene Haas to Step Down After New CEO Appointment

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.